Cardiovascular Risk Factors You Can Control

Heart disease kills roughly 17.9 million people worldwide every year. That is more than cancer, more than infectious disease, more than accidents. The World Health Organization puts cardiovascular conditions at the top of the global mortality table in every year on record, accounting for around 32% of deaths. The statistic is numbing. It is also, in a specific and evidence-backed sense, misleading — because the story the research tells isn't one of inevitable decline. It is a story about which levers you can actually pull, and how large the effect is when you pull them.

The INTERHEART Finding That Should Have Ended the Debate

In 2004, a team led by Salim Yusuf published INTERHEART in The Lancet. It remains one of the most important epidemiological studies ever conducted on heart attack risk. Case-control design. 52 countries. Over 29,000 participants. Every inhabited continent. One question: which factors actually predict a first myocardial infarction?

The answer held together across every geography and every ethnic group examined. Nine modifiable factors accounted for more than 90% of the population-attributable risk of first myocardial infarction. Those nine were: abnormal lipids, current smoking, hypertension, diabetes, abdominal obesity, psychosocial stress, inadequate fruit and vegetable intake, sedentary behavior, and excess alcohol consumption. Not one of the top nine was non-modifiable. Family history, age, and sex matter — but their population-level contribution was dwarfed by the levers individuals and health systems could actually move.

This finding changed how preventive cardiology is taught. It has not, unfortunately, changed how most people think about their own risk.

The 2024 Shift: PREVENT Replaces the Pooled Cohort Equations

For roughly a decade, the default U.S. tool for estimating cardiovascular risk was the ACC/AHA Pooled Cohort Equations — a 10-year ASCVD risk calculator built from older cohort data. In 2024 the American Heart Association introduced a replacement: the PREVENT (Predicting Risk of cardiovascular disease EVENTs) equations, validated on more than 6.5 million contemporary U.S. adults.

PREVENT matters for three reasons. First, it estimates both 10-year and 30-year risk for ages 30 to 79 — the 30-year window is particularly useful for younger patients whose 10-year numbers look deceptively low. Second, it removes race as a variable, addressing a long-standing concern with the Pooled Cohort Equations. Third, and most significantly, it folds kidney function and metabolic health directly into the risk equation via estimated glomerular filtration rate (eGFR), HbA1c, and urine albumin-to-creatinine ratio when available. This reflects the growing recognition that cardiovascular, kidney, and metabolic disease form a single interconnected syndrome — the CKM framework — rather than three separate organ-system problems.

The 2026 ACC/AHA Guideline on the Management of Dyslipidemia now designates PREVENT-ASCVD as the preferred risk estimation tool for adults aged 30 to 79 without known cardiovascular disease.

Blood Pressure: The Multiplier That Runs Silent

The Framingham Heart Study has been tracking cardiovascular outcomes since 1948 in a multigenerational cohort in Massachusetts. Its single most replicated finding is that the relationship between blood pressure and cardiovascular events is continuous and graded. There is no threshold below which risk vanishes. Every 20 mmHg rise in systolic pressure roughly doubles the risk of death from ischemic heart disease and stroke across the range from 115 to 185 mmHg.

The 2017 ACC/AHA guidelines lowered the hypertension threshold from 140/90 to 130/80 mmHg. The 2025 update reaffirmed this classification. The reclassification was controversial but rested on solid evidence — most prominently the NIH-funded SPRINT trial, which found that targeting systolic pressure below 120 mmHg (compared with below 140) reduced cardiovascular events by 25% and all-cause mortality by 27% in high-risk adults.

What makes hypertension particularly dangerous is its multiplicative interaction with other factors. Elevated blood pressure plus elevated LDL cholesterol produces more than the sum of their individual contributions. Add current smoking, and the effect compounds again.

For individuals trying to understand how their own numbers fit into the broader risk picture, cardiovascular risk assessment tools based on established clinical models provide a structured way to contextualize blood pressure alongside lipids, smoking status, glucose, and kidney function — which is how clinicians actually think about cardiovascular risk.

Lipids: Past the Good/Bad Dichotomy

The public mental model of cholesterol is still stuck in the HDL-good, LDL-bad framing of the early 1990s. The field has moved on. Two concepts deserve more attention.

LDL particle number, not just concentration. Two people with identical LDL-C values in mg/dL can carry very different numbers of circulating LDL particles, depending on how much cholesterol each particle is transporting. The person with more, smaller particles faces higher atherosclerotic risk because each particle is an opportunity for arterial wall penetration.

Apolipoprotein B (ApoB). Each atherogenic lipoprotein carries exactly one ApoB molecule, which makes ApoB an effective particle count. A growing body of evidence — including Mendelian randomization studies — suggests ApoB predicts cardiovascular events more accurately than LDL-C, particularly in people with insulin resistance, metabolic syndrome, or hypertriglyceridemia. Some cardiology centers now order ApoB routinely alongside a standard lipid panel.

Triglycerides, once treated as a secondary concern, have also been reassessed. Elevated non-fasting triglycerides correlate with higher remnant cholesterol — a class of atherogenic particles that conventional panels don't always capture.

Smoking: The Biggest Single Lever

Smoking offers the clearest risk-reward calculus in preventive cardiology. Current smokers face roughly two to four times the cardiovascular risk of never-smokers. And cessation works faster than almost any other intervention in medicine. Within 12 months of quitting, excess coronary risk drops by about 50%. Within 5 to 15 years, stroke risk approaches that of a never-smoker.

This reversibility is unusual. Undoing decades of hypertension-driven arterial stiffening takes years of sustained pressure control and may never fully normalize. Removing the inflammatory and endothelial damage of cigarette smoke produces measurable cardiovascular improvement within weeks. If a single intervention deserves top billing in any conversation about modifiable cardiovascular risk, it is this one.

Diabetes, Metabolic Syndrome, and the CKM Cluster

Type 2 diabetes roughly doubles cardiovascular risk. HbA1c and event rates climb together in a dose-dependent way. But diabetes rarely stands alone. The metabolic syndrome cluster — central adiposity, elevated triglycerides, low HDL, elevated blood pressure, and impaired glucose tolerance — represents a package of interacting abnormalities that amplify one another.

Addressing this cluster requires a systems approach rather than hunting down each biomarker individually. A 5 to 10% weight loss, achieved through dietary change and physical activity, simultaneously improves insulin sensitivity, lowers blood pressure, raises HDL, lowers triglycerides, and reduces inflammatory markers. No single pharmaceutical delivers that breadth of downstream benefit.

The newer CKM (cardiovascular-kidney-metabolic) framing, now embedded in the PREVENT equations, recognizes that chronic kidney disease at any stage magnifies cardiovascular risk independently of the traditional factors. Checking eGFR and urine albumin in anyone with diabetes or hypertension is no longer optional best practice — it is guideline-level standard of care.

Physical Inactivity, Quantified

The CDC estimates that physical inactivity contributes to roughly 1 in 10 premature deaths in the United States. The dose-response curve is front-loaded: the largest relative benefit comes from moving out of complete inactivity into even modest weekly activity. Going from sedentary to roughly 150 minutes of moderate exercise per week reduces cardiovascular mortality by 20 to 30% in prospective cohort studies.

The specific modality barely matters. Brisk walking, cycling, swimming, gardening, climbing stairs, structured resistance training — anything that durably raises heart rate above resting baseline contributes. The Framingham data, now spanning three generations, consistently shows that physically active individuals develop cardiovascular disease roughly a decade later than their sedentary peers.

Non-Modifiable Factors: Context, Not Fate

Age, sex, and family history influence baseline risk but do not determine outcomes. A man in his fifties with a brother who had a heart attack at 48 — but who doesn't smoke, exercises, controls his blood pressure, and keeps his ApoB in range — carries meaningfully lower absolute risk than a man with no family history who does none of those things. Genetics set the slope. Modifiable factors determine where on the slope you actually sit.

Polygenic risk scores for coronary artery disease are now robust enough that several clinical genomics programs report them to patients. They help stratify risk, particularly in younger adults with borderline traditional risk profiles. They do not override the evidence that lifestyle and pharmacological risk factor control produces meaningful event reduction at every genetic risk level.

Ranking the Levers

The evidence supports a rough hierarchy of impact:

1. Stop smoking — the single largest, fastest-acting modifiable factor

2. Control blood pressure — target below 130/80 for most adults, lower in high-risk groups

3. Manage ApoB / LDL — through diet, exercise, and statin therapy where indicated

4. Reach 150 minutes of moderate physical activity per week — minimum effective dose

5. Maintain healthy waist circumference — central adiposity drives the metabolic cluster

6. Control glucose — including early intervention in prediabetes

7. Eat adequate fruits, vegetables, and fiber — the Mediterranean pattern has the strongest outcome data

8. Moderate alcohol

9. Address chronic stress and sleep deficits — the two most underappreciated contributors

No one runs this list perfectly. INTERHEART showed that partial risk factor control still produces substantial protection: reducing systolic blood pressure by 10 mmHg, lowering LDL by 1 mmol/L, or adding 150 weekly minutes of walking each independently reduces cardiovascular events by roughly 20 to 25%. Stack two or three of them and the combined effect becomes transformative.

Heart disease is still the leading cause of death globally. But it is increasingly a disease of choice — not in the moralizing sense, but in the empowering one. The levers exist. The effect sizes are large. The tools for estimating individual risk are better than they have ever been. The question now is whether individuals and health systems will act on evidence that has been sitting on the desk for twenty years.

James Whitfield is the Preventive Care Editor at HealthKoLab. He holds an MPH from Johns Hopkins Bloomberg School of Public Health with a concentration in cardiovascular epidemiology.